Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
LianBio (LIAN US)
Watchlist
15
Analysis
Health Care
•
United States
LianBio operates as a biological technology company. The Company develops therapies to treat cardiovascular, oncology, respiratory, ophthalmology and inflammatory disease. LianBio serves customers patients in Asia.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
LianBio
•
30 Jan 2024 20:51
•
Syndicated
Lianbio -Ads (LIAN) - Tuesday, Oct 31, 2023
The company recently sold exclusive rights to develop and commercialize mavacamten in certain areas of Asia to Bristol Myers Squibb for $350 million.
Value Investors Club
Follow
208 Views
Share
bullish
•
Thematic (Sector/Industry)
•
21 Dec 2023 09:30
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
Tina Banerjee
Follow
604 Views
Share
bearish
•
LianBio
•
04 Sep 2023 09:10
LianBio (LIAN.US) - Some Points Worth the Attention
LianBio's pipeline is good, but there’s an “insurmountable obstacle” to license-in mode, making it hard to be breakeven. Approval of Mavacamten is...
Xinyao (Criss) Wang
Follow
393 Views
Share
bullish
•
LianBio
•
01 Sep 2023 17:39
LianBio (LIAN US): Lead Asset Is Approaching Commercialization; Satisfactory Cash Runway
LianBio's lead asset mavacamten is undergoing review in China for symptomatic obstructive hypertrophic cardiomyopathy, with approval expected in...
Tina Banerjee
Follow
572 Views
Share
bullish
•
LianBio
•
18 Apr 2023 17:32
LianBio (LIAN US): 2023 Is Going to Be Data Heavy; Current Cash Runway Raises Commercialization Hope
This year, LianBio expects to report late-stage trial data, initiate clinical trials, and file marketing approval for lead drug candidate in China....
Tina Banerjee
Follow
379 Views
Share
1
2
3
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.40.5
x